Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sir John Bell

- PMLiVE

Wilmington Healthcare appoints new director to lead cloud-based healthcare customer intelligence tool

Paul Rowe to lead intelligence tool that allows Industry to gain the complete picture of their changing NHS customer base and employ precision planning to access target customers and markets.

Wilmington Healthcare

- PMLiVE

UK government announce £260m to boost healthcare research and manufacturing

This investment will help the NHS deliver new life-saving treatments to patients more efficiently and will help to support more diverse and inclusive clinical research

- PMLiVE

Fishawack Health expands its value, evidence, and market access capabilities with the acquisition of HEOR consultancy Policy Analysis Inc. (PAI)

Fishawack Health announces its expanded global Value, Evidence, and Access (VEA) capability for biopharmaceutical and medical technology companies, with a suite of end-to-end services spanning product lifecycle, coupled with unsurpassed...

Avalere Health

- PMLiVE

NICE recommends Amgen’s Lumykras for non-small-cell lung cancer

Lung cancer is recorded as being the third most common cancer, with an estimated 48,000 new cases diagnosed in the UK every year

White paper: Are we prepared for the influx of CAR-Ts?

Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies

Research Partnership

- PMLiVE

NHS trusts set a 90% target for electronic patient records by UK health secretary

Current estimates indicate that one in five NHS trusts still do not have electronic patient records

- PMLiVE

Seagen’s Tukysa granted NICE recommendation for breast cancer patients

Approximately 400 patients are expected to benefit from the treatment in England and Wales annually

- PMLiVE

NICE recommends GSK’s Zejula for patients with ovarian cancer

In the UK there are over 40,000 women with ovarian cancer

- PMLiVE

London High Court rules in favour of NHS in Servier drug dispute

The judgement is a key milestone in the 11-year case between the French pharmaceutical company and the secretary of state for health and social care and the wider NHS

LOOKING AHEAD: UNDERSTANDING THE NHS CUSTOMER’S PRIORITIES FOR 2022/23

The recently published operational planning guidance describes what the NHS needs to achieve this year. Wilmington Healthcare’s Oli Hudson explores some of its critical themes and what they mean for...

Wilmington Healthcare

- PMLiVE

No green light from NICE for innovative cancer treatments

The Institute of Cancer Research is asking for more flexibility and consideration to make it easier for cancer patients to access new treatments on the NHS

- PMLiVE

NICE recommends AZ’s Forxiga for kidney disease

The recommendation is based on results from a phase 3 trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links